Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Adagene $161 million IPO
We advised Adagene on its IPO and Nasdaq listing
Cornell Capital acquires trustaff and CardioSolution in combination with Stella
We are advising Cornell Capital on the acquisition
Bolt Biotherapeutics $230 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Immunocore $297 million IPO
We advised the joint book-running managers and underwriters on the IPO and Nasdaq listing
Terns Pharmaceuticals $127.5 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Revolution Medicines $300 million follow-on offering
We advised the underwriters in connection with the equity offering
Ocumension Therapeutics HK$793.8 million top-up placement of shares
We advised the placing agent in connection with the equity offering
Venus Medtech HK$1.4 billion placing of new H shares
We advised Venus Medtech (Hangzhou) on its placement of new shares
CureVac $450 million public offering
We advised CureVac on the equity offering
Seer $251.3 million stock offering
We advised the underwriters on the SEC-registered equity offering